merck's hcv drug bring's in only $21 million, page-19

Saverio,the current trials will involve significantly higher doses of bit225 than phasel trials.This will hopefully provide a much more significant impact on the hepC virus as was demonstrated in phasel that an increase in dosage equated to an increase in effectiveness and if results prove significant this will be reflected in the SP.

The follow up trials on HIV is elephant country(much like successful cancer treatments HIV treatments attract a different level of publicity and investor interest).

BIT225 will possibly belong to a unique group of compounds that can treat multiple diseases/viruses.Add to that the tight nature of the register and low market cap with the funds to take us through to the end of hiv trials there is quite a lot riding on the success of HCV trials from a shareholders point of veiw...GL Holders.